Mouwasat Medical Services Company (TADAWUL:4002) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Investors in Mouwasat Medical Services Company (TADAWUL:4002) had a good week, as its shares rose 10.0% to close at ر.س78.30 following the release of its quarterly results. Results look mixed - while revenue fell marginally short of analyst estimates at ر.س764m, statutory earnings were in line with expectations, at ر.س0.99 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Taking into account the latest results, the current consensus from Mouwasat Medical Services' twelve analysts is for revenues of ر.س3.11b in 2025. This would reflect an okay 6.5% increase on its revenue over the past 12 months. Per-share earnings are expected to swell 10% to ر.س3.70. In the lead-up to this report, the analysts had been modelling revenues of ر.س3.23b and earnings per share (EPS) of ر.س3.72 in 2025. The consensus seems maybe a little more pessimistic, trimming their revenue forecasts after the latest results even though there was no change to its EPS estimates.

Check out our latest analysis for Mouwasat Medical Services

The average price target was steady at ر.س97.13even though revenue estimates declined; likely suggesting the analysts place a higher value on earnings. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Mouwasat Medical Services analyst has a price target of ر.س132 per share, while the most pessimistic values it at ر.س75.00. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Mouwasat Medical Services' past performance and to peers in the same industry. We can infer from the latest estimates that forecasts expect a continuation of Mouwasat Medical Services'historical trends, as the 8.8% annualised revenue growth to the end of 2025 is roughly in line with the 9.2% annual growth over the past five years. Compare this with the broader industry (in aggregate), which analyst estimates suggest will see revenues grow 12% annually. So although Mouwasat Medical Services is expected to maintain its revenue growth rate, it's forecast to grow slower than the wider industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. On the negative side, they also downgraded their revenue estimates, and forecasts imply they will perform worse than the wider industry. Still, earnings are more important to the intrinsic value of the business. The consensus price target held steady at ر.س97.13, with the latest estimates not enough to have an impact on their price targets.

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Mouwasat Medical Services going out to 2027, and you can see them free on our platform here..

It might also be worth considering whether Mouwasat Medical Services' debt load is appropriate, using our debt analysis tools on the Simply Wall St platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.